PALM INTRANET

Day : Monday
Date: 6/30/2003
Time: 11:48:26

Inventor Name Search Result

Your Search was:

Last Name = DODGE
First Name = JEFFREY

Application#	Patent#	Status	Date Filed	Title	Inventor Name
60397869	Not Issued	020	07/22/2002	SELECTIVE ESTROGEN RECEPTOR MODULATORS	DODGE, JEFFREY ALAN
60363622	Not Issued	020	03/11/2002	SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS	DODGE, JEFFREY ALAN
60361524	Not Issued	020	03/01/2002	SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS	DODGE, JEFFREY ALAN
60355891	Not Issued	020	02/11/2002	SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS	DODGE, JEFFREY ALLAN
60332766	Not Issued	020	11/19/2001	CYCLOALKYLBENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS	DODGE, JEFFREY ALAN
10380867	Not Issued	030	03/14/2003	SUBSTITUTED DIPEPTIDES AS GROWTH HORMONE SECRETAGOGUES	DODGE, JEFFREY ALAN
10349521	Not Issued	094	01/22/2003	SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS	DODGE, JEFFREY ALAN
09890163	Not Issued	030	07/25/2001	GROWTH HORMONE SECRETAGOGUES	DODGE, JEFFREY ALAN
09852597	Not Issued	030	05/10/2001	SYSTEMS AND METHODS FOR NOTIFYING A CONSUMER OF CHANGES MADE TO A CREDIT REPORT	DODGE, JEFFREY L.
09644110	6407201	150	08/21/2000	NOVEL PLASTICIZERS FOR BOWLING BALL COVERSTOCKS	DODGE, JEFFREY A.
09486019	Not Issued	161	02/18/2000	GROWTH HORMONE SECRETAGOGUES	DODGE, JEFFREY A.
09482432	6291484	150	01/13/2000	BENZOTHIOPHENES	DODGE,

					JEFFREY ALAN
09134319	Not Issued	161	08/14/1998	METHODS FOR INHIBITING FIBROUS INFLAMMATORY DISEASE AND RIEDEL'S THYROIDITIS	DODGE , JEFFREY A
09129119	6509356	150	08/04/1998	1-(4-(SUBSTITUTED ALKOXY) BENZYL) NAPHTHALENE COMPOUNDS HAVING ESTROGEN INHIBITORY ACTIVITY	DODGE , JEFFREY
08680475	5631247	150	07/15/1996	COMPOUNDS AND COMPOSITIONS WITH NITROGEN-CONTAINING NON-BASIC SIDE CHAINS	DODGE , JEFFREY A.
08679593	5811421	150	07/16/1996	NAPHTHYL AND DIHYDRONAPHTHYL INTERMEDIATES, COMPOUNDS, COMPOSITIONS, AND METHODS	DODGE , JEFFREY A.
08567451	Not Issued	161	12/05/1995	NOVEL NAPHTHYL PHARMACEUTICAL COMPOUNDS	DODGE , JEFFREY A
08442917	5719165	150	05/17/1995	METHODS OF INHIBITING OVARIAN DYSGENESIS, DELAYED PUBERTY, OR SEXUAL INFANTILISM	DODGE , JEFFREY A.
08442707	5552417	150	05/17/1995	METHODS OF INHIBITING SEXUAL PRECOCITY	DODGE , JEFFREY A.
08438855	Not Issued	161	05/10/1995	BENZOFURAN COMPOUNDS COMPOSITIONS AND METHODS	DODGE , JEFFREY A.
08438461	Not Issued	161	05/10/1995	BENZOFURAN COMPOUNDS, COMPOSITIONS, AND METHODS	DODGE , JEFFREY A.
08438334	Not Issued	071	05/10/1995	BENZOFURAN COMPOUNDS, COMPOSITIONS, AND METHODS	DODGE , JEFFREY A.
08437903	Not Issued	161	05/10/1995	BENZOFURAN COMPOUNDS, COMPOSITIONS, AND METHODS	DODGE , JEFFREY A.
08435437	6407243	150	05/10/1995	BENZOFURAN COMPOUNDS, COMPOSITIONS, AND METHODS	DODGE , JEFFREY A.
08428924	5484797	150	04/21/1995	NAPHTHLY COMPOUNDS, INTERMEDIATES, PROCESSES, COMPOSITIONS, AND METHOD FOR INHIBITING ENDOMETRIOSIS	DODGE , JEFFREY A.
08428922	6410564	150	04/21/1995	NAPHTHYL COMPOUNDS, INTERMEDIATES, PROCESSES, COMPOSITIONS, AND METHODS	DODGE , JEFFREY A.

08426770	5484796	150	04/21/1995	NAPHTHYL COMPOUNDS, INTERMEDIATES, PROCESSES, COMPOSITIONS, AND METHOD OF INHIBITING AORTAL SMOOTH MUSCLE CELL PROLIFERATION.	DODGE , JEFFREY A.
08426766	Not Issued	161	04/21/1995	NAPHTHYL COMPOUNDS, INTERMEDIATES, PROCESSES, COMPOSITIONS, AND METHODS	DODGE , JEFFREY A
08426552	Not Issued	094	04/21/1995	BENZOTHIOPHENES WITH NOVEL BASIC SIDE CHAINS	DODGE , JEFFREY A.
08426542	5484795	150	04/21/1995	NAPHTHYL COMPOUNDS, INTERMEDIATES, PROCESSES, COMPOSITIONS, AND METHOD OF INHIBITING RESTENOSIS	DODGE , JEFFREY A.
08426347	Not Issued	168	04/21/1995	NAPHTHYL COMPOUNDS, INTERMEDIATES, PROCESSES, COMPOSITIONS, AND METHODS	DODGE , JEFFREY A.
08426339	Not Issued	161	04/21/1995	BENZOTHIOPHENES WITH NOVEL BASIC SIDE CHAINS	DODGE , JEFFREY A.
08426321	Not Issued	168	04/21/1995	NAPHTHYL COMOUNDS, INTERMEDIATES, PROCESSES, COMPOSITIONS, AND METHODS	DODGE , JEFFREY A.
08426318	6437137	150	04/21/1995	NAPHTHYL COMPOUNDS, INTERMEDIATES, PROCESSES, COMPOSITIONS, AND METHODS	DODGE , JEFFREY A.
08424989	5484798	150	04/19/1995	BENZOTHIOPHENE COMPOUNDS, COMPOSITIONS, AND METHOD OF INHIBITING RESTENOSIS.	DODGE , JEFFREY A.
08424988	5492921	150	04/19/1995	BENZOTHIOPHENE COMPOUNDS, COMPOSITIONS, AND METHODS FOR INHIBITING AORTAL SMOOTH MUSCLE PROLIFERATION.	DODGE , JEFFREY A.
08424987	Not Issued	071	04/19/1995	BENZOTHIOPHENE COMPOUNDS, COMPOSITIONS, AND METHODS	DODGE , JEFFREY A.
08424985	Not Issued	041	04/19/1995	BENZOTHIOPHENE COMPOUNDS COMPOSITIONS AND METHODS	DODGE , JEFFREY A.
08423498	6399634	150	04/19/1995	BENZOTHIOPHENE COMPOUNDS, COMPOSITIONS, AND METHODS	DODGE , JEFFREY A.
08419484	5472977	150	04/10/1995	METHODS FOR THE TREATMENT OF UTERINE FIBROID DISEASE	DODGE , JEFFREY A.
08419230	5843976	150	04/10/1995	METHODS FOR LOWERING SERUM CHOLESTEROL AND INHIBITING SMOOTH MUSCLE CELL PROLIFERATION,	DODGE , JEFFREY A.

				RESTENOSIS, ENDOMETRIOSIS, AND UTERINE FIBROID DISEASE	
08404701	5567820	150	03/15/1995	GLUCOPYRANOSIDE BENZOTHIOPHENES	DODGE , JEFFREY A.
08404692	Not Issued	163	03/15/1995	GLUCOPYRANOSIDE BENZOTHIOPHENES	DODGE , JEFFREY A.
08395944	6479517	150	02/28/1995	PHOSPHOROUS-CONTAINING BENZOTHIOPHENES	DODGE , JEFFREY A.
08171393	5451590	150	12/21/1993	METHODS OF INHIBITING SEXUAL PRECOCITY	DODGE , JEFFREY A.
08171328	5441966	150	12/21/1993	METHODS OF INHIBITING TURNER'S SYNDROME	DODGE , JEFFREY A.
08170946	5451589	150	12/21/1993	METHODS OF INHIBITING OVARIAN DYSGENESIS, DELAYED PUBERTY, OR SEXUAL INFANTILISM	DODGE , JEFFREY A.
08168482	5596004	150	12/21/1993	METHODS OF INHIBITING MALE INFERTILITY	DODGE , JEFFREY A.
08134337	Not Issued	166	10/12/1993	INHIBITION OF PHOSPHATIDYLINOSITOL 3-KINASE WITH VIRIDIN, DEMETHOXYVIRIDIN, VIRIDIOL, DEMETHOXYVIRIDIOL, VIRONE, WORTMANNOLONE, AND ANALOGS THEREOF	DODGE , JEFFREY A.
08112012	Not Issued	161	08/25/1993	METHODS FOR INHIBITING BONE LOSS AND CARTILAGE DEGRADATION USING WORTMANNIN AND ITS ANALOGS	DODGE , JEFFREY A.
08111796	5441947	150	08/25/1993	METHODS OF INHIBITING VASCULAR RESTENOSIS	DODGE , JEFFREY A.

Search and Display More Records.

Search Another: Inventor

Last Name Dodge **First Name** jeffrey

Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

```
=> d l3
L3 HAS NO ANSWERS
L3                STR
```



```
VAR G1=HY/25
VPA 15-1/5 U
NODE ATTRIBUTES:
NSPEC   IS C      AT  26
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   4
NUMBER OF NODES IS  26

STEREO ATTRIBUTES: NONE


=> s l3
SAMPLE SEARCH INITIATED 11:37:44 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     44 TO ITERATE

100.0% PROCESSED      44 ITERATIONS                          24 ANSWERS
SEARCH TIME: 00.00.03

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          483 TO     1277
PROJECTED ANSWERS:             187 TO      773

L5            24 SEA SSS SAM L3

=> s l3 ful
FULL SEARCH INITIATED 11:37:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    721 TO ITERATE

100.0% PROCESSED     721 ITERATIONS                     406 ANSWERS
SEARCH TIME: 00.00.03

L6           406 SEA SSS FUL L3

=> fil caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             148.15     157.56
```

FILE 'CAPLUS' ENTERED AT 11:38:02 ON 30 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Jun 2003 VOL 139 ISS 1
FILE LAST UPDATED: 29 Jun 2003 (20030629/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l6
L7 7 L6

=> d bib abs 1-7

L7 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2003 ACS
AN 2002:314919 CAPLUS
DN 136:325545
TI Resolution process for preparation of substantially pure (R) and (S) enantiomers of 2-(4-nitroimidazolyl)--2-(4-methoxyphenyl)propionic acid and salts thereof
IN Kress, Thomas Joseph; Robey, Roger Lewis; Wepsiec, James Patrick; Alt, Charles Arthur; Rhodes, Gary Anthony
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002032878	A1	20020425	WO 2001-US27739	20010928

W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2000-240350P P 20001013
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A method is disclosed for obtaining a single enantiomer of 2-(4-nitroimidazolyl)-2-(4-methoxyphenyl)propionic acid. The method involves reacting I with a resolving agent selected from the group consisting of levamisole, quinidine, brucine, (+)-cinchonine, (-)-cinchonidine, (1R,2S)-ephedrine and (1S,2R)-ephedrine in a solvent to produce a cryst. salt, isolating the salt and optionally converting to the free acid. For example a mixt. of I (10 g, 34.3 mmol), levamisole (free base; 7.8 g, 38.2 mmol) in Et acetate (150 mL) was stirred at reflux to give a yellow soln. The soln. cooled to 25.degree.C and was seeded to afford a thick slurry which was filtered at 0.degree.C and vacuum dried. The crude salt was re-slurried in hot Et acetate and filtered to afford a salt that when acidified afforded free acid (-)-(R)-I in 99.4% ee by chiral capillary electrophoresis. An enantiomer of I is used in the synthesis of II, a growth hormone secretagogue. Resoln. of intermediate I is less costly than chromatog. sepn. of II.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS
AN 2001:868261 CAPLUS
DN 136:696
TI Combination of growth hormone secretagogues and antidepressants for improving the physical and psychological condition of patients undergoing a medical procedure and for treating various conditions
IN Busch, Frank Robert; Welch, Willard McKowan, Jr.
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001089570	A2	20011129	WO 2001-IB815	20010510
	WO 2001089570	A3	20020620		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1284753	A2	20030226	EP 2001-928149	20010510
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001011002	A	20030415	BR 2001-11002	20010510
	US 2002002137	A1	20020103	US 2001-860786	20010518
PRAI	US 2000-207017P	P	20000525		
	WO 2001-IB815	W	20010510		

OS MARPAT 136:696
AB This invention is directed to combinations comprising a growth hormone secretagogue, a prodrug thereof or a pharmaceutically acceptable salt of said growth hormone secretagogue or said prodrug and an antidepressant, a prodrug thereof or a pharmaceutically acceptable salt of said antidepressant or said prodrug and to pharmaceutical compns. and kits comprising such combinations. Antidepressants within the scope of this invention include norepinephrine reuptake inhibitors (e.g., secondary and tertiary amine tricyclics), selective sertraline reuptake inhibitors, agents which are combined norepinephrine/sertraline reuptake inhibitors, monoamine oxidase inhibitors and atypical antidepressants. This invention

is also directed to methods of improving the phys. and/or psychol. condition of a patient undergoing a medical procedure, to methods of treating musculoskeletal frailty, to methods of treating congestive heart failure and to methods of attenuating protein catabolic response after a major operation comprising administering such a combination. In particular, this invention relates to such compns. and kits that improve the cardiac function, metab., muscle tone and/or mental state of patients undergoing a medical procedure. The compns. and kits of this invention are also useful in treating central nervous system disorders of patients undergoing a medical procedure.

L7 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2003 ACS
AN 2000:592737 CAPLUS
DN 133:193495
TI Preparation of heterocyclic peptide derivatives as growth hormone secretagogues
IN Dodge, Jeffrey Alan; Lugar, Charles Willis, III
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 230 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000049037	A1	20000824	WO 2000-US4274	20000218
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1153034	A1	20011114	EP 2000-913536	20000218
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000008321	A	20020129	BR 2000-8321	20000218
	JP 2002539089	T2	20021119	JP 2000-599774	20000218
PRAI	US 1999-120813P	P	19990219		
	WO 2000-US4274	W	20000218		

OS MARPAT 133:193495
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Peptides I [R1 = PhCH2OCH2, Ph(CH2)3, indol-3-ylmethyl; Y = pyrrolidinyl, 4-methylpiperidinyl, dialkylamino; R3 = 2-naphthyl, Ph or 4-WC6H4 (W = F, CF3, alkoxy, phenyl); R4 = H, Me] or their pharmaceutically acceptable salts or solvates were prepd. as growth hormone secretagogues. Formulations contg. I are described. Thus, peptide II.2CF3CO2H (Aib = .alpha.-aminoisobutyric acid) was prepd. and showed EC50 = 5.53 .mu.M in a pituitary cell culture assay for growth hormone secretion.
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS
AN 2000:438762 CAPLUS
DN 133:130066

TI Effect of growth hormone secretagogue LY444711 on IGF-1, growth hormone, and cortisol levels in beagle dogs after one and seven daily oral doses
AU Seyler, David E.; Dodge, Jeffrey A.; Osborne, John J.; Cox, Karen L.; Viswanath, Devanarayan; Wilmot, Anita F.; Keaton, M. Joni; Heiman, Mark L.; Bryant, Henry U.; Cutler, Gordon B., Jr.
CS Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
SO Drug Development Research (2000), 49(4), 260-265
CODEN: DDREDK; ISSN: 0272-4391
PB Wiley-Liss, Inc.
DT Journal
LA English
AB Growth hormone (GH) release involves interaction of somatostatin and an endogenous GH secretagogue (GHS) on the hypothalamus. GH causes release of IGF-1, which acts by neg. feedback to restrain subsequent GH release. GH secretagogues produce increases in cortisol. In this study, the authors detd. if compd. LY444711 produces sustained elevation of GH and IGF-1 in beagle dogs without sustained alteration of baseline cortisol secretions after one and seven daily doses. Adult male beagle dogs received oral doses of LY444711 at 1 mg/kg/day, or vehicle (10% hydroxypropyl beta-cyclodextrin). Jugular vein blood was collected periodically after one and seven doses, and plasma levels of IGF-1, GH, and cortisol were detd. LY444711 increased IGF-1 levels by approx. 60% over controls after one and seven daily doses. IGF-1 was elevated within 6 h of dosing on Day 1 and remained elevated 24 h postdose. GH levels (AUC) increased approx. 50-fold above controls following a single dose of LY444711. With repeated dosing, GH levels rose to approx. 8-fold over controls. Regardless of the redn. in GH AUC with repeat dosing, sufficient GH was produced to cause sustained IGF-1 elevation after seven doses. LY444711 produced little or no effect on cortisol AUC level after one or seven doses. These data demonstrate that LY444711 functions as a GH secretagogue in dogs, with assocd. increases in IGF-1 levels and an absence of meaningful increases in cortisol levels.
RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS
AN 2000:222866 CAPLUS
DN 132:313797
TI Development of analytical and preparative chromatographic separations of novel growth hormone secretagogue compounds
AU Kennedy, Joseph H.; Bowers, John L.; Dodge, Jeffrey A.; Lugar, Charles W.; Shepherd, Timothy A.; Sharp, V. Scott
CS Chemical Process Research and Development, Lilly Research Laboratories, A Division of Eli Lilly Company, Indianapolis, IN, 46060, USA
SO Journal of Chromatography, A (2000), 872(1+2), 75-84
CODEN: JCRAEY; ISSN: 0021-9673
PB Elsevier Science B.V.
DT Journal
LA English
AB Chromatog. sepns. of new growth hormone secretagogue compds. were developed to support structure-activity relationship (SAR) studies in conjunction with lead optimization. These new compds. differed from Merck's MK-677 by having two chiral centers and thus diastereomeric mixts. were generated. Sepn. of initial compds. in the SAR was achieved on a Kromasil C18 column using an ammonium acetate buffer and acetonitrile. However, addnl. candidates were not separable on C18 columns and a chiral Kromasil CHI-DMB column was used to resolve the diastereomeric compds. The Kromasil CHI-DMB packing was also used in a preparative chromatog. system to resolve multigram quantities of secretagogue candidates for testing. Chiral sepns. of different intermediates were also developed in support of evolution of an asym. synthetic route. This report summarizes development of the preparative chromatog. system used to purify diastereomeric mixts. and chiral sepns. of intermediates in the synthesis.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2003 ACS
AN 1999:141228 CAPLUS
DN 130:182769
TI Preparation of heterocyclic peptide derivatives as growth hormone secretagogues
IN Dodge, Jeffrey Alan; Hauser, Kenneth Lee; Heiman, Mark Louis; Jones, Scott Alan; Alt, Charles Arthur; Bryant, Henry Uhlman; Cohen, Jeffrey Daniel; Copp, James Densmore; Fahey, Kennan Joseph; Gritton, William Harlan; Jungheim, Louis Nickolaus; Kennedy, Joseph Henry; Lugar, Charles Willis, III; Muehl, Brian Stephen; Palkowitz, Alan David; Ratz, Andrew Michael; Rhodes, Gary Anthony; Robey, Robert Lewis; Seyler, David Edward; Shepherd, Timothy Alan; Thrasher, Kenneth Jeff; Trankle, William George
PA Eli Lilly and Compay, USA
SO PCT Int. Appl., 876 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9908699	A1	19990225	WO 1998-US17229	19980819
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	ZA 9807385	A	20000418	ZA 1998-7385	19980817
	EP 933365	A2	19990804	EP 1998-306622	19980818
	EP 933365	A3	20030319		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	CA 2302467	AA	19990225	CA 1998-2302467	19980819
	AU 9890256	A1	19990308	AU 1998-90256	19980819
	AU 738204	B2	20010913		
	BR 9811948	A	20000822	BR 1998-11948	19980819
	JP 2001515046	T2	20010918	JP 2000-509436	19980819
	CA 2340344	AA	20000302	CA 1999-2340344	19990219
	WO 2000010565	A1	20000302	WO 1999-US3525	19990219
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9926868	A1	20000314	AU 1999-26868	19990219
	EP 1112071	A1	20010704	EP 1999-907136	19990219
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002523368	T2	20020730	JP 2000-565886	19990219
	NO 2000000823	A	20000412	NO 2000-823	20000218
PRAI	US 1997-56142P	P	19970819		
	EP 1998-306621	A	19980818		
	EP 1998-306622	A	19980818		
	WO 1998-US17229	W	19980819		

WO 1999-US3525 W 19990219
OS MARPAT 130:182769
GI



I



II



III

AB This invention relates to novel title compds. I [A = C1-6 alkyl, aryl, C1-6 alkylaryl, C1-6 alkyl-O-C1-6 alkylaryl, C1-6 alkyl-S-C1-6 alkylaryl, indolyl, indolinyl, thienyl, C1-6 alkylthienyl, benzothienyl, benzofuranyl, naphthyl, cyclohexyl, etc.; B = NH2, substituted amino, alkylamino, alkylcycloalkylamino, nitrogen heterocycle; X = C1-6 alkylidenyl, O, S, NH, N-C1-6 alkyl; V = C6H4, nitrogen-contg. heterocycle; D = any group A, C1-6 alkyl-SO2-aryl, C1-6 alkyl-SO2-C1-6 alkyl; E = H, any group A, CO-C1-6 alkyl, aryl-CONH2, etc.; or D and E form indanyl, fluorenyl, or cycloalkyl ring; G = H, C1-6 alkyl, aryl, C1-6 alkylaryl, C1-6 alkenyl; J = H, C1-6 alkyl, aryl, C1-6 alkylaryl; L = H, C1-6 alkyl, CO2-C1-6 alkyl, aryl, C1-6 alkylaryl, CO2-C1-6 alkylaryl, C1-6 alkenyl, F, CN, C1-6 alkyl-OH, C1-6 alkyl-O-C1-6 alkyl, etc.] and pharmaceutically acceptable salts and hydrates thereof, which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compds., as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compds. Thus, catalytic redn. of nitroimidazole dipeptide II (prepn. given), followed by sequential peptide coupling with Boc-Ser(CH2Ph)-OH and Boc-Aib-OH (Aib = .alpha.-aminoisobutyric acid) and deprotection, gave desired peptide deriv. III. III showed EC50 = 2.39 mM in a pituitary cell culture assay for growth hormone secretion.
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2003 ACS
AN 1999:141226 CAPLUS
DN 130:209977
TI Treatment of congestive heart failure with growth hormone secretagogues
IN Kauffman, Raymond Francis; Palkowitz, Alan David
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 775 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9908697	A1	19990225	WO 1998-US17201	19980819
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	ZA 9807383	A	20000217	ZA 1998-7383	19980817
	EP 898963	A2	19990303	EP 1998-306621	19980818
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9803168	A	20000111	BR 1998-3168	19980818
	CA 2300848	AA	19990225	CA 1998-2300848	19980819
	AU 9894715	A1	19990308	AU 1998-94715	19980819
	JP 2001515045	T2	20010918	JP 2000-509434	19980819
	JP 2002523368	T2	20020730	JP 2000-565886	19990219
	US 6329342	B1	20011211	US 2000-485924	20000218
PRAI	US 1997-56135P	P	19970819		
	WO 1998-US17201	W	19980819		
	WO 1999-US3525	W	19990219		

OS MARPAT 130:209977
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; A = alkyl, aryl, alkylaryl, etc.; B = NH2, alkylNH2, alkylarylNH2, etc.; X = alkylidenyl, O, S, etc.; V = II-IV, etc.; D = H, alkyl, alkylOC(O)alkyl, etc.; E = H, alkyl, aryl, etc.; DE = indanyl, fluorenyl, cycloalkyl; G = H, alkyl, aryl, etc.; J = H, alkyl, aryl, alkylaryl; L = H, alkyl, aryl, etc.] and their pharmaceutically acceptable salts, useful for the modulation of cardiac function by the administration of a growth hormone secretagogue, which results in an increase in the levels of endogenous growth hormone, were prepd. and formulated. E.g., a multi-step synthesis of V which showed EC50 of 5.53 .mu.M against GH secretion, was given. Further provided are methods for the treatment of congestive heart failure by the administration of a growth hormone secretagogue in combination with a growth hormone releasing hormone, or in combination with an antihypertensive agent, diuretic, or other suitable agents.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d hitstr 6

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2003 ACS
IT **220540-73-8P 220540-75-0P 220540-79-4P**
220540-83-0P 220540-87-4P 220540-92-1P
220540-96-5P 220540-99-8P 220541-03-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of heterocyclic peptide derivs. as growth hormone secretagogues)

RN 220540-73-8 CAPLUS
CN D-Tryptophanamide, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-N-[1-[2-oxo-1-phenyl-2-(1-pyrrolidinyl)ethyl]-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220540-75-0 CAPLUS
CN L-Proline, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-D-tryptophyl-4-amino-.alpha.-phenyl-1H-imidazole-1-acetyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220540-79-4 CAPLUS
CN D-Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-3-(2-naphthalenyl)-N-[1-[2-oxo-1-phenyl-2-(1-pyrrolidinyl)ethyl]-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220540-83-0 CAPLUS
CN D-Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-N-[1-[2-(4-methyl-1-piperidinyl)-2-oxo-1-phenylethyl]-1H-imidazol-4-yl]-3-(2-naphthalenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220540-87-4 CAPLUS
CN D-Phenylalaninamide, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-N-[1-[2-oxo-1-phenyl-2-(1-pyrrolidinyl)ethyl]-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220540-92-1 CAPLUS
CN D-Phenylalaninamide, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-N-[1-[2-(4-methyl-1-piperidinyl)-2-oxo-1-phenylethyl]-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220540-96-5 CAPLUS
CN Carbamic acid, [1,1-dimethyl-2-oxo-2-[[(1R)-1-[[[1-[2-oxo-1-phenyl-2-(1-pyrrolidinyl)ethyl]-1H-imidazol-4-yl]amino]carbonyl]-3-phenylpropyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220540-99-8 CAPLUS
CN Carbamic acid, [1,1-dimethyl-2-[[(1R)-1-[[[1-[2-(4-methyl-1-piperidinyl)-2-oxo-1-phenylethyl]-1H-imidazol-4-yl]amino]carbonyl]-3-phenylpropyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220541-03-7 CAPLUS
CN L-Proline, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-(.alpha.R)-.alpha.-aminobenzenebutanoyl-4-amino-.alpha.-phenyl-1H-imidazole-1-acetyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **220536-62-9P 220536-63-0P 220536-64-1P**
220536-65-2P 220536-66-3P 220536-67-4P
220536-68-5P 220536-69-6P 220536-70-9P
220536-74-3P 220536-76-5P 220536-78-7P
220536-79-8P 220536-80-1P 220536-81-2P
220536-86-7P 220536-87-8P 220536-88-9P
220536-90-3P 220536-91-4P 220536-92-5P
220536-94-7P 220536-95-8P 220536-96-9P
220536-97-0P 220536-99-2P 220537-02-0P
220537-04-2P 220537-07-5P 220537-08-6P
220537-09-7P 220537-11-1P 220537-12-2P
220537-14-4P 220537-15-5P 220537-16-6P
220537-17-7P 220537-18-8P 220537-19-9P
220537-20-2P 220537-21-3P 220537-22-4P
220537-24-6P 220537-28-0P 220537-29-1P
220537-32-6P 220537-33-7P 220537-35-9P
220537-36-0P 220537-37-1P 220537-39-3P
220537-40-6P 220537-41-7P 220537-42-8P
220537-43-9P 220537-44-0P 220537-45-1P
220537-47-3P 220537-48-4P 220537-50-8P
220537-51-9P 220537-52-0P 220537-54-2P
220537-55-3P 220537-56-4P 220537-57-5P
220537-58-6P 220537-70-2P 220537-72-4P
220537-73-5P 220537-74-6P 220537-75-7P
220537-77-9P 220537-78-0P 220537-79-1P
220537-81-5P 220537-82-6P 220537-83-7P

220537-85-9P 220537-86-0P 220537-87-1P
220537-88-2P 220537-89-3P 220537-90-6P
220537-91-7P 220537-93-9P 220537-94-0P
220537-95-1P 220537-96-2P 220537-97-3P
220537-99-5P 220538-00-1P 220538-01-2P
220538-02-3P 220538-03-4P 220538-04-5P
220538-05-6P 220538-06-7P 220538-08-9P
220538-10-3P 220538-11-4P 220538-12-5P
220538-13-6P 220538-14-7P 220538-15-8P
220538-16-9P 220538-17-0P 220538-19-2P
220538-20-5P 220538-21-6P 220538-23-8P
220538-24-9P 220538-25-0P 220538-26-1P
220538-27-2P 220538-28-3P 220538-29-4P
220538-30-7P 220538-31-8P 220538-32-9P
220538-33-0P 220539-07-1P 220539-08-2P
220539-15-1P 220539-16-2P 220539-51-5P
220539-53-7P 220539-54-8P 220539-55-9P
220539-56-0P 220539-57-1P 220539-60-6P
220539-69-5P 220539-70-8P 220539-71-9P
220539-72-0P 220539-80-0P 220539-85-5P
220539-86-6P 220539-87-7P 220539-88-8P
220539-89-9P 220539-91-3P 220539-97-9P
220539-99-1P 220540-01-2P 220540-02-3P
220540-03-4P 220540-07-8P 220540-09-0P
220540-10-3P 220540-13-6P 220540-15-8P
220540-17-0P 220540-22-7P 220540-24-9P
220540-30-7P 220540-32-9P 220540-35-2P
220540-38-5P 220540-41-0P 220540-44-3P
220540-47-6P 220540-49-8P 220540-52-3P
220540-55-6P 220540-58-9P 220540-61-4P
220540-64-7P 220540-68-1P 220540-71-6P
220540-77-2P 220540-81-8P 220540-85-2P
220540-89-6P 220540-94-3P 220540-97-6P
220541-01-5P 220541-05-9P 220541-06-0P
220541-08-2P 220541-10-6P 220541-73-1P
220541-74-2P 220541-75-3P 220541-84-4P
220605-02-7P 220632-26-8P 220632-27-9P
220632-28-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heterocyclic peptide derivs. as growth hormone secretagogues)

RN 220536-62-9 CAPLUS
<------User Break------>

=> d hitstr 7

L7 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2003 ACS
IT **220540-73-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(treatment of congestive heart failure with growth hormone secretagogues)
RN 220540-73-8 CAPLUS
CN D-Tryptophanamide, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-N-[1-[2-oxo-1-phenyl-2-(1-pyrrolidinyl)ethyl]-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 220536-62-9P 220536-63-0P 220536-64-1P
220536-65-2P 220536-66-3P 220536-67-4P
220536-68-5P 220536-74-3P 220536-76-5P
220536-78-7P 220536-79-8P 220536-80-1P
220536-81-2P 220536-86-7P 220536-87-8P
220536-88-9P 220536-90-3P 220536-91-4P
220536-92-5P 220536-94-7P 220536-95-8P
220536-96-9P 220536-97-0P 220536-99-2P
220537-02-0P 220537-04-2P 220537-07-5P
220537-08-6P 220537-09-7P 220537-11-1P
220537-12-2P 220537-14-4P 220537-15-5P
220537-16-6P 220537-17-7P 220537-18-8P
220537-19-9P 220537-20-2P 220537-21-3P
220537-22-4P 220537-24-6P 220537-28-0P
220537-29-1P 220537-32-6P 220537-33-7P
220537-35-9P 220537-36-0P 220537-37-1P
220537-39-3P 220537-40-6P 220537-41-7P
220537-42-8P 220537-43-9P 220537-44-0P
220537-45-1P 220537-47-3P 220537-48-4P
220537-50-8P 220537-51-9P 220537-52-0P
220537-54-2P 220537-55-3P 220537-56-4P
220537-57-5P 220537-58-6P 220537-70-2P
220537-72-4P 220537-73-5P 220537-74-6P
220537-75-7P 220537-77-9P 220537-78-0P
220537-79-1P 220537-82-6P 220537-83-7P
220537-85-9P 220537-86-0P 220537-87-1P
220537-88-2P 220537-89-3P 220537-90-6P
220537-91-7P 220537-93-9P 220537-94-0P
220537-95-1P 220537-96-2P 220537-97-3P
220537-99-5P 220538-00-1P 220538-01-2P
220538-02-3P 220538-03-4P 220538-04-5P
220538-05-6P 220538-06-7P 220538-08-9P
220538-10-3P 220538-11-4P 220538-12-5P
220538-13-6P 220538-14-7P 220538-15-8P
220538-16-9P 220538-17-0P 220538-19-2P
220538-20-5P 220538-21-6P 220538-23-8P
220538-24-9P 220538-25-0P 220538-26-1P
220538-27-2P 220538-28-3P 220538-29-4P
220538-30-7P 220538-31-8P 220538-32-9P
220538-33-0P 220539-07-1P 220539-08-2P
220539-15-1P 220539-16-2P 220539-51-5P
220539-53-7P 220539-54-8P 220539-55-9P
220539-56-0P 220539-57-1P 220539-60-6P
220539-71-9P 220539-72-0P 220539-85-5P
220539-86-6P 220539-87-7P 220539-88-8P

220539-89-9P 220539-91-3P 220539-97-9P
220539-99-1P 220540-01-2P 220540-02-3P
220540-03-4P 220540-07-8P 220540-09-0P
220540-10-3P 220540-13-6P 220540-15-8P
220540-17-0P 220540-22-7P 220540-24-9P
220540-30-7P 220540-35-2P 220540-38-5P
220540-41-0P 220540-44-3P 220540-47-6P
220540-49-8P 220540-52-3P 220540-55-6P
220540-58-9P 220540-61-4P 220540-64-7P
220540-68-1P 220540-71-6P 220540-75-0P
220540-77-2P 220540-79-4P 220540-81-8P
220540-83-0P 220540-85-2P 220540-87-4P
220540-89-6P 220540-92-1P 220540-94-3P
220540-96-5P 220540-97-6P 220540-99-8P
220541-01-5P 220541-05-9P 220605-02-7P
220632-26-8P 220632-27-9P 220632-28-0P
220907-34-6P 220907-39-1P 220907-40-4P
220907-41-5P 220907-42-6P 220907-53-9P
220907-54-0P 220907-56-2P 220907-66-4P
220907-67-5P 220907-68-6P 220907-69-7P
220907-76-6P 220907-77-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(treatment of congestive heart failure with growth hormone secretagogues)

RN 220536-62-9 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-[1-[(1S)-1-(4-methoxyphenyl)-2-(4-methyl-1-piperidinyl)-2-oxoethyl]-1H-imidazol-4-yl]-O-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

2 HCl

RN 220536-63-0 CAPLUS

CN D-Serinamide, 2-methylalanyl-N-[1-[(1R)-1-(4-methoxyphenyl)-2-(4-methyl-1-piperidinyl)-2-oxoethyl]-1H-imidazol-4-yl]-O-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

●2 HCl

RN 220536-64-1 CAPLUS
CN D-Serinamide, 2-methylalanyl-N-[1-[(1S)-2-[4-(4-fluorobenzoyl)-1-piperidinyl]-1-(4-methoxyphenyl)-2-oxoethyl]-1H-imidazol-4-yl]-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220536-65-2 CAPLUS
CN D-Serinamide, 2-methylalanyl-N-[1-[(1R)-2-[4-(4-fluorobenzoyl)-1-piperidinyl]-1-(4-methoxyphenyl)-2-oxoethyl]-1H-imidazol-4-yl]-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220536-66-3 CAPLUS
CN D-Serinamide, 2-methylalanyl-N-[1-[1-(4-methoxyphenyl)-2-oxo-2-(1-piperidinyl)ethyl]-1H-imidazol-4-yl]-O-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

2 HCl

RN 220536-67-4 CAPLUS
CN D-Proline, 2-methylalanyl-O-(phenylmethyl)-D-seryl-4-amino-.alpha.-(4-methoxyphenyl)-1H-imidazole-1-acetyl-, methyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 220536-68-5 CAPLUS
CN D-Norvalinamide, 2-methylalanyl-N-[1-[1-(4-methoxyphenyl)-2-(4-methyl-1-piperidinyl)-2-oxoethyl]-1H-imidazol-4-yl]-5-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

2 HCl

RN 220536-74-3 CAPLUS
CN D-Serinamide, 2-methylalanyl-N-[1-[1-(3,4-dimethoxyphenyl)-2-(4-methyl-1-

piperidinyl)-2-oxoethyl]-1H-imidazol-4-yl]-O-(phenylmethyl)-,
dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

●2 HCl

RN 220536-76-5 CAPLUS
CN D-Serinamide, 2-methylalanyl-N-[1-[(1R)-2-(4-methyl-1-piperidinyl)-2-oxo-1-[4-(trifluoromethyl)phenyl]ethyl]-1H-imidazol-4-yl]-O-(phenylmethyl)-,
dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

2 HCl

RN 220536-78-7 CAPLUS
CN D-Serinamide, 2-methylalanyl-N-[1-[(1S)-2-(4-methyl-1-piperidinyl)-2-oxo-1-[4-(trifluoromethyl)phenyl]ethyl]-1H-imidazol-4-yl]-O-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

●2 HCl

RN 220536-79-8 CAPLUS
CN D-Serinamide, 2-methylalanyl-N-[1-[2-[4-(4-fluorobenzoyl)-1-piperidinyl]-2-oxo-1-[4-(trifluoromethyl)phenyl]ethyl]-1H-imidazol-4-yl]-O-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

●2 HCl

RN 220536-80-1 CAPLUS
CN D-Tryptophanamide, 2-methylalanyl-N-[1-[(1R)-2-(4-methyl-1-piperidinyl)-2-oxo-1-[4-(trifluoromethyl)phenyl]ethyl]-1H-imidazol-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

2 HCl

RN 220536-81-2 CAPLUS
CN D-Tryptophanamide, 2-methylalanyl-N-[1-[(1S)-2-(4-methyl-1-piperidinyl)-2-oxo-1-[4-(trifluoromethyl)phenyl]ethyl]-1H-imidazol-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

●2 HCl

RN 220536-86-7 CAPLUS
CN D-Serinamide, 2-methylalanyl-N-[1-[(1R)-1-(4-fluorophenyl)-2-(4-methyl-1-piperidinyl)-2-oxoethyl]-1H-imidazol-4-yl]-O-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

●2 HCl

RN 220536-87-8 CAPLUS
CN D-Serinamide, 2-methylalanyl-N-[1-[(1S)-1-(4-fluorophenyl)-2-(4-methyl-1-piperidinyl)-2-oxoethyl]-1H-imidazol-4-yl]-O-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

2 HCl

2 HCl

RN 220536-88-9 CAPLUS
CN D-Serinamide, 2-methylalanyl-N-[1-[1-(4-fluorophenyl)-2-oxo-2-(1-pyrrolidinyl)ethyl]-1H-imidazol-4-yl]-O-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 220536-90-3 CAPLUS
CN D-Serinamide, 2-methylalanyl-N-[1-[2-[4-(4-fluorobenzoyl)-1-piperidinyl]-1-(4-fluorophenyl)-2-oxoethyl]-1H-imidazol-4-yl]-O-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 2-A

2 HCl

RN 220536-91-4 CAPLUS
CN D-Norvalinamide, 2-methylalanyl-N-[1-[(1R)-1-(4-fluorophenyl)-2-(4-methyl-1-piperidinyl)-2-oxoethyl]-1H-imidazol-4-yl]-5-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

●2 HCl

RN 220536-92-5 CAPLUS
CN D-Norvalinamide, 2-methylalanyl-N-[1-[(1S)-1-(4-fluorophenyl)-2-(4-methyl-1-piperidinyl)-2-oxoethyl]-1H-imidazol-4-yl]-5-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

●2 HCl

RN 220536-94-7 CAPLUS
CN D-Serinamide, 2-methylalanyl-N-[1-[1-(3,4-difluorophenyl)-2-(4-methyl-1-piperidinyl)-2-oxoethyl]-1H-imidazol-4-yl]-O-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

2 HCl

RN 220536-95-8 CAPLUS
CN D-Serinamide, 2-methylalanyl-N-[1-[1-(3,4-difluorophenyl)-2-oxo-2-(1-pyrrolidinyl)ethyl]-1H-imidazol-4-yl]-O-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 220536-96-9 CAPLUS
CN D-Serinamide, 2-methylalanyl-N-[1-[1-(3,4-difluorophenyl)-2-[4-(4-fluorobenzoyl)-1-piperidinyl]-2-oxoethyl]-1H-imidazol-4-yl]-O-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

2 HCl

RN 220536-97-0 CAPLUS
CN D-Serinamide, 2-methylalanyl-N-[1-[1-(2,4-difluorophenyl)-2-(4-methyl-1-

piperidinyl)-2-oxoethyl]-1H-imidazol-4-yl]-O-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

●2 HCl

RN 220536-99-2 CAPLUS
CN D-Serinamide, 2-methylalanyl-N-[1-[1-(2,4-difluorophenyl)-2-oxo-2-(1-pyrrolidinyl)ethyl]-1H-imidazol-4-yl]-O-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



2 HCl

RN 220537-02-0 CAPLUS
CN D-Serinamide, 2-methylalanyl-N-[1-[(1R)-1-(4-ethoxyphenyl)-2-(4-methyl-1-piperidinyl)-2-oxoethyl]-1H-imidazol-4-yl]-O-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

<------User Break------>
[

PAGE 1-A



PAGE 2-A

●2 HCl

RN 220537-04-2 CAPLUS
CN D-Serinamide, 2-methylalanyl-N-[1-[(1S)-1-(4-ethoxyphenyl)-2-(4-methyl-1-piperidinyl)-2-oxoethyl]-1H-imidazol-4-yl]-O-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



2 HCl

RN 220537-07-5 CAPLUS
CN D-Serinamide, 2-methylalanyl-N-[1-[1-(4-ethoxyphenyl)-2-oxo-2-(1-pyrrolidinyl)ethyl]-1H-imidazol-4-yl]-O-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.